Literature DB >> 26081907

Bridging the Gap in Neurotherapeutic Discovery and Development: The Role of the National Institute of Neurological Disorders and Stroke in Translational Neuroscience.

Meghan Mott1, Walter Koroshetz.   

Abstract

The mission of the National Institute of Neurological Disorders and Stroke (NINDS) is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease. NINDS supports early- and late-stage therapy development funding programs to accelerate preclinical discovery and the development of new therapeutic interventions for neurological disorders. The NINDS Office of Translational Research facilitates and funds the movement of discoveries from the laboratory to patients. Its grantees include academics, often with partnerships with the private sector, as well as small businesses, which, by Congressional mandate, receive > 3% of the NINDS budget for small business innovation research. This article provides an overview of NINDS-funded therapy development programs offered by the NINDS Office of Translational Research.

Entities:  

Mesh:

Year:  2015        PMID: 26081907      PMCID: PMC4489962          DOI: 10.1007/s13311-015-0366-6

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  4 in total

1.  The challenge of translational research--a perspective from the NINDS.

Authors:  Robert Finkelstein; Thomas Miller; Robert Baughman
Journal:  Nat Neurosci       Date:  2002-11       Impact factor: 24.884

2.  NINDS translational programs: priming the pump of neurotherapeutics discovery and development.

Authors:  Rajesh Ranganathan
Journal:  Neuron       Date:  2014-11-05       Impact factor: 17.173

3.  Neurology's stake in foundational neuroscience research.

Authors:  Walter J Koroshetz; Story Landis
Journal:  JAMA Neurol       Date:  2014-09       Impact factor: 18.302

Review 4.  Improving and accelerating drug development for nervous system disorders.

Authors:  Diana E Pankevich; Bruce M Altevogt; John Dunlop; Fred H Gage; Steve E Hyman
Journal:  Neuron       Date:  2014-11-05       Impact factor: 17.173

  4 in total
  4 in total

1.  Synthesis, In Silico and Pharmacological Evaluation of New Thiazolidine-4-Carboxylic Acid Derivatives Against Ethanol-Induced Neurodegeneration and Memory Impairment.

Authors:  Shagufta Naz; Lina Tariq Al Kury; Humaira Nadeem; Fawad Ali Shah; Aman Ullah; Rehan Zafar Paracha; Muhammad Imran; Shupeng Li
Journal:  J Inflamm Res       Date:  2022-06-25

2.  Benzimidazole Derivatives as New Potential NLRP3 Inflammasome Inhibitors That Provide Neuroprotection in a Rodent Model of Neurodegeneration and Memory Impairment.

Authors:  Aman Ullah; Lina Tariq Al Kury; Yusuf S Althobaiti; Tahir Ali; Fawad ALi Shah
Journal:  J Inflamm Res       Date:  2022-07-11

Review 3.  Sex differences in the blood-brain barrier and neurodegenerative diseases.

Authors:  Callie M Weber; Alisa Morss Clyne
Journal:  APL Bioeng       Date:  2021-03-16

Review 4.  Disease modification and Neuroprotection in neurodegenerative disorders.

Authors:  Jeffrey Cummings
Journal:  Transl Neurodegener       Date:  2017-09-26       Impact factor: 8.014

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.